Cinon0.1%

Cinon is a high-potency (Class II) synthetic topical corticosteroid used to relieve the inflammation, redness, and itching associated with corticosteroid-responsive dermatoses.

Established / FDA-approved uses

• Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, including psoriasis (excluding widespread plaque psoriasis), atopic dermatitis/eczema, contact dermatitis, lichen planus, and other chronic inflammatory skin disorders.

Guideline-supported / commonly used for

• Localized, resistant, thickened lesions (e.g., lichenified eczema, hypertrophic lichen planus, discoid lupus erythematosus lesions of the skin) where a higher-potency agent is judged necessary by the treating physician, generally for short, defined courses.

Cinon is not intended for use on the face, groin, axillae, or under diapers, and is not indicated for ophthalmic, oral, or intravaginal use (see Precautions and Warnings).

Each gram of Halcinonide cream/topical solution contains 1 mg (0.1% w/w) of Halcinonide as the active ingredient, in a cream or solution base.

Cinon is a synthetic, fluorinated corticosteroid formulated for topical dermatologic use, classified as a high-potency (Class II) topical corticosteroid. It is available as a 0.1% cream and, in some markets, as a topical solution.

Cinon works locally on the skin to reduce inflammation, itching, and redness in corticosteroid-responsive skin conditions. It is intended for external use on the skin only and should not be applied to the eyes, mouth, or vaginal mucosa.

Topical Corticosteroid (High-Potency, Class II, Synthetic Fluorinated Corticosteroid)

Pharmacodynamics

Halcinonide, like other topical corticosteroids, has anti-inflammatory, antipruritic, and vasoconstrictive properties. It diffuses across cell membranes and binds to cytoplasmic glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This induces synthesis of lipocortin-like proteins that inhibit phospholipase A2, thereby reducing release of arachidonic acid and downstream inflammatory mediators (prostaglandins and leukotrienes). The net effect is suppression of local inflammation, capillary dilation, and leukocyte infiltration at the application site.

Pharmacokinetics

The extent of percutaneous absorption of Halcinonide depends on the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Absorption is increased by inflamed or denuded skin, application to thin-skinned areas (face, groin, axillae), and occlusion. Once absorbed, Halcinonide is handled like systemically administered corticosteroids: it is metabolized primarily in the liver and excreted mainly by the kidneys, with some biliary excretion.

Cinon is for external (topical) use on the skin only. Wash and dry hands before and after application. Apply a thin film and gently rub into the affected area; avoid contact with the eyes, mouth, and mucous membranes. Do not cover with an occlusive (airtight) dressing unless specifically instructed by a physician. Avoid application to the face, groin, and armpits (axillae) unless directed otherwise.

Because Cinon is applied topically and systemic absorption is normally minimal, clinically significant drug-drug interactions are uncommon. Clinically relevant interactions relate mainly to additive effects on corticosteroid exposure:

• Other topical or systemic corticosteroids: Concurrent use of other corticosteroid-containing products on the same skin area, or systemic corticosteroid therapy, can increase total corticosteroid exposure and the risk of HPA-axis suppression and skin atrophy; avoid combining unless directed by a physician.
• Occlusive agents/dressings and other topical products at the same site: Co-application of other topical agents, emollients under occlusion, or dressings can increase percutaneous absorption of Cinon and the risk of systemic corticosteroid effects.

Local (common)

• Burning, stinging, itching, or irritation at the application site
• Dryness of the skin
• Folliculitis and acneiform eruptions
• Hypertrichosis (excess hair growth)
• Perioral dermatitis and allergic contact dermatitis
• Skin atrophy, striae, telangiectasia, and hypopigmentation, particularly with prolonged use
• Maceration of the skin and secondary skin infection

Systemic (uncommon, generally with extensive/prolonged use or occlusion)

• Hypothalamic-pituitary-adrenal (HPA) axis suppression (see Precautions and Warnings)
• Cushingoid features, hyperglycemia, and glucosuria with extensive, prolonged application

Pregnancy: There are no adequate and well-controlled studies of Cinon in pregnant women. Topical corticosteroids can be absorbed systemically in sufficient amounts to produce fetal effects in animal studies. Cinon should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under medical supervision; avoid use over large body surface areas, for prolonged periods, or under occlusion during pregnancy.

Lactation: It is not known whether topical administration of Cinon results in sufficient systemic absorption to produce detectable amounts in human milk. Caution should be exercised when Cinon is used by a nursing mother; avoid applying it directly to the breast/nipple area before breastfeeding, and consult a physician before use.

Cinon is a high-potency topical corticosteroid, and the following precautions apply:

• HPA-axis suppression: Systemic absorption can occur, especially with use over large body-surface areas, under occlusive dressings, on damaged/inflamed skin, or with prolonged use, and may produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Periodic evaluation for HPA-axis suppression may be warranted with extensive or prolonged use.
• Sensitive skin areas: Avoid use on the face, groin, and axillae, and avoid prolonged use in these areas, because of thinner skin and higher absorption; this increases the risk of atrophy, striae, and telangiectasia.
• Occlusion: Do not use occlusive dressings unless specifically directed by a physician, as occlusion markedly increases percutaneous absorption and the risk of systemic effects; occlusive dressings, including diapers, should be avoided in children.
• Infection: If a skin infection develops or worsens during treatment, discontinue Cinon and institute appropriate antimicrobial therapy (see Contraindications for untreated infections).
• Not for eye, oral, or vaginal use: Cinon should not be used in or near the eyes, or on mucous membranes.
• Duration of use: Limit treatment to the shortest effective duration and reassess if no improvement is seen (see Duration of Treatment); avoid abrupt discontinuation after prolonged, extensive use, since this may unmask latent HPA-axis suppression.

Acute toxicity from a single topical application of Cinon is unlikely. However, chronic excessive use, application over large areas of skin, or use under occlusion can result in sufficient systemic absorption to produce features of hypercortisolism (Cushing's syndrome), hyperglycemia, and HPA-axis suppression. If Cinon is accidentally ingested, or if signs of systemic corticosteroid excess (unusual weight gain, moon face, muscle weakness, or high blood sugar) develop, seek immediate medical attention or contact a poison control center/emergency services. Do not attempt to manage suspected overdose or systemic toxicity at home.

Store at room temperature (below 30°C), away from light and moisture. Do not expose to excessive heat. Keep the tube tightly closed and out of reach of children.

Pediatric use

Children may be more susceptible to HPA-axis suppression and Cushing's syndrome than mature individuals because of a larger skin-surface-area-to-body-weight ratio. Cinon should be used in children only if clearly needed, in the smallest effective amount, and for the shortest duration; occlusive dressings, including plastic pants and tightly fitting diapers, should generally be avoided. Safety and efficacy of long-term use in children have not been established.

Geriatric use

Clinical studies of Cinon have not identified differences in response between elderly and younger patients; however, elderly patients may have thinner skin and should be monitored for signs of atrophy with prolonged use.

Hepatic/renal impairment

No specific dosage adjustment is established; caution is advised if extensive-area or occluded application is used in patients with hepatic impairment, given the potential for increased systemic corticosteroid exposure.

Pregnancy and lactation

See Pregnancy and Lactation section above.

Because Cinon is a high-potency corticosteroid, treatment should generally be limited to short courses. Many corticosteroid-responsive dermatoses respond within 2 weeks; if no improvement is seen within this period, the diagnosis should be reassessed by a physician. Prolonged, uninterrupted use beyond 2–3 weeks, or use over large areas, should only continue under direct medical supervision because of increased risk of skin atrophy and HPA-axis suppression.

Topical Corticosteroids; High-Potency (Class II) Synthetic Fluorinated Corticosteroids

Halcinonide binds to intracellular glucocorticoid receptors in skin cells, and the activated receptor complex modulates gene expression to induce anti-inflammatory proteins (such as lipocortins) that inhibit phospholipase A2. This reduces the production of inflammatory mediators (prostaglandins, leukotrienes), decreases capillary permeability and vasodilation, and suppresses migration of inflammatory cells to the site of application, producing the anti-inflammatory, antipruritic, and vasoconstrictive effects that relieve corticosteroid-responsive skin conditions.

C

Cinon may be used in children for corticosteroid-responsive dermatoses, but only under medical supervision, using the smallest effective amount for the shortest possible duration, because children have a higher skin-surface-area-to-body-weight ratio and are more prone to HPA-axis suppression and systemic corticosteroid absorption than adults. Occlusive dressings and tightly fitting diapers should be avoided in pediatric patients using Cinon. Safety and efficacy for long-term, unsupervised, or widespread use in children have not been established.